Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE.
OBJECTIVE
To assess the impact of ethnicity, age, and ocular characteristics on ranibizumab efficacy in myopic choroidal neovascularization (CNV).


METHODS
In this post hoc subgroup analysis from the phase III RADIANCE study, best-corrected visual acuity (BCVA) outcomes and treatment exposure were analyzed in 105 patients treated with ranibizumab 0.5 mg. Baseline categories included ethnicity, age, baseline BCVA, lesion area, CNV lesion area, refraction sphere, axial length, subretinal fluid, and location of CNV.


RESULTS
At month 12, the mean change in BCVA was numerically higher in East-Asians than in Caucasians (17.0 vs. 14.1 letters). The median number of injections varied with ethnicity (East-Asians vs. Caucasians: 2 vs. 3), baseline BCVA (highest vs. lowest: 1 vs. 4), CNV lesion area and lesion area (largest vs. smallest: 5 vs. 1 and 5 vs. 2).


CONCLUSIONS
East-Asians showed numerically higher BCVA gains than Caucasians. The number of injections varied across subgroups, emphasizing the need for individualized treatment.
Department of Ophthalmology, University of Bonn, Bonn, Germany.
Frank G
FG
Holz
Adnan
A
Tufail
Nicolas
N
Leveziel
Timothy Y Y
TY
Lai
Paolo
P
Lanzetta
Tien Y
TY
Wong
Hyeong Gon
HG
Yu
You Xin
YX
Chen
Nikol
N
Heinrichs
Stefan
S
Pilz
Kyoko
K
Ohno-Matsui
D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000208:ethnology / Q000209:etiology; D004311:Double-Blind Method; D005006:Ethnicity; D005260:Female; D005500:Follow-Up Studies; D014943:Global Health; D006801:Humans; D015994:Incidence; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications* / Q000208:ethnology / Q000503:physiopathology; D000069579:Ranibizumab / Q000008:administration & dosage*; D012160:Retina / Q000187:drug effects / Q000473:pathology*; D012307:Risk Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab